Registration is open for
ASIPP's 2025 Annual Meeting
We would love it if you would register and join us in Orlando!
| |
Attention Fellows and Residents! | |
|
ASIPP is pleased to announce a scholarship to help fellows and residents participate in the 2025 ASIPP Annual Meeting. Recipients of this scholarship will receive reimbursement for up to three nights stay at the host hotel at the official ASIPP single-occupancy room block rate. This includes room block room rate and tax.
The number of scholarship recipients will be limited so it is important to apply soon!
| |
Abstract submissions are open for
ASIPP's 2025 Annual Meeting!
The abstract submission deadline is March 10, 2025.
Don't miss this opportunity to share your insights
and help shape the future of pain management.
| |
|
Amid a deluge of executive actions, the Trump administration has asked federal health agencies to pause external communications, such as regular scientific reports, updates to websites and health advisories, according to sources within the agencies.
The orders were delivered Tuesday to staff at agencies inside the US Department of Health and Human Services, including to officials at the US Food and Drug Administration, the US Centers for Disease Control and Prevention and National Institutes of Health, according to the Washington Post, which first reported the story.
The direction came without warning and with little guidance as to what exactly it covered, according to sources inside the affected agencies who asked not to be named because they were not authorized to share the information. One source said the reason for the pause and its duration were not communicated.
Read More
| |
Agendas for ASIPP's
Virtual Review Courses Are Here!
| |
Private practices offer personalized care, expanded access, and physician autonomy
With today's medical advancements and technologies, innovation in the surgical field is creating possibilities for patients that did not exist a few years ago. I utilize these new techniques to care for my patients with fewer side effects, faster recovery times, and better health outcomes.
Though the demand for surgery remains, trusted surgeons -- particularly those in independent practices -- may soon be in short supply. According to the Association of American Medical Colleges, our country will be short 15,800 to 30,200 surgeons by 2034. One contributing factor is the high cost of medical education, which discourages students from entering the surgical profession and creates substantial debt for those who do.
Of the few that go on to work in the surgical field, even fewer are entering private practice. That's because ongoing reimbursement cuts for physicians are pushing newly trained surgeons into hospital-based jobs. In speaking with private-practice surgeons across the country, I consistently hear how this trend is threatening our ability to continue to provide high-quality care in the communities we serve, especially to patients in underserved areas who must travel farther for care. Congress must act quickly to address these trends and uphold the cornerstones of independent medicine.
Read More
| |
Evidence supports narrow indication for intervertebral injections of condoliase, advisors say
FDA advisors largely supported the regulatory approval of condoliase for nerve pain associated with lumbar disc herniation (LDH) if it can be targeted to the right patients.
During Friday's meeting of the Anesthetic and Analgesic Drug Products Advisory Committee, members voted 8-4 in support of the approval of condoliase, noting that the benefits of the intervertebral injection outweigh the risks when used to treat radicular leg pain associated with confirmed nerve root impingement caused by LDH in adults. If approved, condoliase would be the first biologic or drug green-lit for lumbosacral radicular pain.
Patients with this condition have been seeking relief, with varying degrees of success, from an array of nonpharmacologic, off-label pharmacologic, and device-based therapies. After failing on these conservative therapies -- including physical therapy, nonsteroidal anti-inflammatory drugs, acetaminophen, drugs for neuropathic pain, systemic steroids, spinal cord stimulation, and percutaneous discectomy -- some patients will resort to surgery.
Read More
| |
|
No additional risk in older adults newly prescribed the drug, comparative analysis shows
New use of gabapentin (Neurontin) was not associated with greater risk of falls in older adults with neuropathy or fibromyalgia compared with new use of duloxetine (Cymbalta), a commercial claims analysis suggested.
At 30, 90, and 180 days, the weighted cumulative incidence of a fall-related visit was 103.60, 90.44, and 84.44 per 1,000 person-years for new gabapentin users and 203.43, 177.73, and 158.21 for new duloxetine users, reported Alexander Chaitoff, MD, MPH, of the University of Michigan in Ann Arbor, and co-authors.
At 6-month follow-up, new gabapentin users had lower hazard of falls (HR 0.52, 95% CI 0.43-0.64), Chaitoff and colleagues wrote in Annals of Internal Medicine. However, there was no significant difference between gabapentin and duloxetine in the hazards of experiencing a severe fall with hip fracture (HR 0.78, 95% CI 0.32-1.86) or hospitalization associated with a fall (HR 0.68, CI 0.42-1.11).
Read More
| |
|
New 2025 Dates
Mark your calendars!
February 15, March 1, & March 29
Four (4) hour virtual exam
- ABIPP Path – Combined CCPM/ CSM Exam
For those with subspecialty in Pain Medicine
Two (2) hour virtual exam
- ABIPP Competency Exam in IPM
For those without primary board certification
Two (2) hour virtual exam
- ABIPP Competency Exam in Regenerative Medicine
Two (2) hour virtual exam
- Controlled Substance Management Competency Exam
Two (2) hour virtual exam
- Documentation, Coding, Compliance, Practice Management Competency Exam
Two (2) hour virtual exam
| |
|
Clinical utility of the FDA-approved test isn't clear, researchers say
A new study questioned the clinical utility of an algorithm meant to predict opioid use disorder (OUD) risk based on 15 genetic variants.
In a case-control analysis of more than 450,000 adults, the 15 variants collectively accounted for just 0.40% of the variation in OUD risk, according to Henry Kranzler, MD, of the University of Pennsylvania Perelman School of Medicine in Philadelphia, and co-authors. In comparison, age and sex alone accounted for 3.27% of the variance.
A machine-learning model using the 15 variants as predictive factors correctly identified case and control status 52.83% (95% CI 52.07-53.59) of the time, Kranzler and colleagues reported in JAMA Network Open.
Read More
| |
- ASIPP Members Only Site Information - | |
-
To log in for the first time you will need to click “forgot password” at the bottom of the login window.
- Check your email and then log in as directed.
-
If you have problems logging into your account, click here.
| |
|
IMGs must work 3 years in underserved areas before being fully licensed
Massachusetts has passed a law that drops residency requirements for international medical graduates (IMGs) and provides an alternative pathway to permanent licensure.
Late last fall, Gov. Maura Healey (D) signed into law the Physician Pathway Act, which requires IMGs to spend at least 3 years practicing at healthcare facilities in rural or underserved areas. It was folded into a larger economic development bill, according to Boston.com.
Hao Yu, PhD, a health policy expert at Harvard Medical School in Boston who has been following the recent growth of state laws aimed at easing licensure for IMGs, told MedPage Today that Massachusetts is now one of 10 states that have passed such laws.
Read More
| | |
| |
REGISTRATION
COMING SOON!
| | |
|
The prescribing information for two respiratory syncytial virus (RSV) vaccines will now include a warning for the increased risk for Guillain-Barré Syndrome (GBS) within 42 days of vaccination based on data from postmarketing research, according to a safety communication from the US Food and Drug Administration (FDA).
Concerns about GBS arose during the review of safety data from clinical trials prior to the approval of Abrysvo (manufactured by Pfizer) and Arexvy (manufactured by GlaxoSmithKline), according to the FDA communication. Based on these findings, the FDA required the manufacturers to conduct additional studies to assess GBS as a condition of approval.
The postmarketing study involved Medicare claims data from May 2023 through July 2024, using a risk window of 1-42 days after vaccination and a control window of 43-90 days after vaccination.
Read More
| |
Upcoming ASIPP State Society Meetings | |
Join the Louisiana Society of
Interventional Pain Physicians (LSIPP)
2025 Annual Meeting on February 20
6 pm (CST) at Juban's Restaurant in Baton Rouge, LA
| |
|
After an historic rate hike cycle that was the fastest on record and largest in decades, the Federal Reserve announced its first rate cut since 2020 this past September.
The Federal Reserve (Fed) began lowering rates in a measured manner to maintain a healthy, growing economy and jobs market without fueling additional inflation, a scenario referred to as a “soft landing.”
During the Fed’s hawkish period starting in March 2022, U.S. inflation has dropped from a more than 40-year high of 9.1% down to 2.5%. While the latest inflation number remains above the Fed’s 2% target, “the committee has gained greater confidence that inflation is moving sustainably toward 2%, and judges that the risks to achieving its employment and inflation goals are roughly in balance,” according to the latest Fed statement.
Read More
| |
|
Pain Medicine Case Reports (PMCR) and Editor-in-Chief Alaa Abd-Elsayed, MD, PhD would like to invite you to submit case reports and case series to the PMCR journal. Your article will be published free of charge.
Open access journals are freely available online for immediate worldwide open access to the full text of published articles. There is no subscription fee for open access journals. Open access journals are no different from traditional subscription-based journals: they undergo the same peer review and quality control as any other scholarly journal.
Interested in becoming a member of the PMCR Editorial Board?
Editorial board members are asked to review 2-6 manuscripts per year. Please submit your most up-to-date CV to sgold@asipp.org for consideration.
For more information or to submit your articles, click here.
| |
|
Emanuel Narcis Husu, MD, Edward S. Yoon, MD, Neal H. Shonnard, MD, Justine Norwitz, MD, Nell Shonnard, BS, and Douglas P. Beall, MD
Abstract
BACKGROUND: There is little data on the economics of the timing of percutaneous vertebral augmentation (PVA) for vertebral compression fractures (VCFs).
CASE REPORT: The purpose of this case series is to compare health care utilization (HCU) costs vs the time to treatment (TTT) of the VCF. The BenchMarket Medical VCF Registry (now Talosix) was utilized. Patients receiving acute or intermediate treatment had the greatest pain and function improvement and the lowest HCU costs. Patients receiving delayed treatment had the least improvement and the highest (3-fold) HCU costs. Any TTT delay resulted in higher HCU costs and diminished benefits. The most beneficial PVA outcome and lowest HCU costs were recorded in patients whose PVA was expedited and performed within 3 months from injury.
CONCLUSIONS: This series suggests the best pain and function improvement and lowest HCU costs result from efficient, timely PVA.
KEY WORDS: Vertebroplasty, kyphoplasty, health care economics, registry, osteoporotic fracture, health care overutilization, case series
Read More
| |
RANDOMIZED CONTROLLED TRIAL | |
|
Jin Wang, MD, Feng Xia, MD, Li-Ying Wang, MD, Li-Zhong Wang, MD, Xiang-Yang Chang, MD, Zhi-Yu Meng, MM, and Chang-Na Wei, MD
Abstract
BACKGROUND: Visceral pain is common in cesarean sections conducted under combined spinal-epidural anesthesia (CSE). Epidural volume extension (EVE) is a technique for enhancing the effect of intrathecal blocks by inducing epidural fluid boluses in the CSE. Whether EVE that uses different drugs can reduce visceral pain during cesarean sections is rarely studied.
OBJECTIVES: In this study, we compared the effect of EVE that used low-dose sufentanil, either alone or combined with low-concentration ropivacaine, on visceral pain during cesarean sections under CSE.
STUDY DESIGN: A prospective, randomized controlled study.
SETTING: The study was performed in the Jiaxing University Affiliated Women and Children Hospital.
METHODS: We randomly allocated 100 healthy patients to 4 groups to receive spinal hyperbaric bupivacaine followed by EVE with 10 mL of 0.9% saline (Group NS), 10 mL of 0.15% ropivacaine (Group R), 10 mL of 10 mu-g sufentanil (Group S), or a combination of 10 mL of 0.15% ropivacaine and 10 mu-g sufentanil (Group RS) through the epidural catheter 15 minutes thereafter. The primary outcome was the incidence of visceral pain. Each occurrence of visceral pain during the procedure was recorded. Every patient’s pain level was evaluated on the visual analog scale (VAS). The consumption of sufentanil during patient-controlled intravenous analgesia (PCIA) and patient satisfaction scores under anesthesia were recorded within 48 hours after surgery. Maximum sensory block levels, segmental increases after EVE, time for sensory regression to the tenth thoracic dermatome (T10), and time for motor recovery to modified Bromage 0 were compared among each group.
RESULTS: Visceral pain occurred in 60% (15/25), 56% (14/25), 24% (6/25) and 12% (3/25) of patients in the NS, R, S, and RS groups, respectively. The incidence of visceral pain was significantly lower in the RS group than in the NS or R groups (P < 0.05) but not significantly different from the S group. The S and RS groups have significantly lower VAS scores compared to the NS and R groups (P < 0.05). Sufentanil consumption during PCIA in the R and RS groups was significantly lower than in the NS group. Patients’ overall intraoperative satisfaction scores were significantly higher in the S and RS groups than in the NS or R groups.
LIMITATIONS: This study has limitations in its sample size, time point of EVE implementation, absence of laboratory indicators, and lack of assessment of postoperative visceral pain, necessitating future studies to address these issues.
CONCLUSIONS: EVE at 15 minutes after spinal anesthesia with a 10 mL combination of low-dose sufentanil (10 mu-g) and low-concentration (0.15%) ropivacaine can effectively reduce the incidence and severity of visceral pain in cesarean sections under CSE. At the same time, using EVE in this way can reduce postoperative opioid consumption and improve intraoperative satisfaction.
KEY WORDS: Sufentanil, ropivacaine, visceral pain, epidural volume extension (EVE), cesarean
Read More
| |
RANDOMIZED CONTROLLED TRIAL | |
|
Xixia Feng, MD, Xueyin Zhao, MD, Ruihao Zhou, MS, Lu Chen, MD, Guo Chen, MD, Tao Zhu, MD, and Ling Ye, MD
Abstract
BACKGROUND: High-voltage (65 V) long-duration pulsed radiofrequency (HL-PRF) is an effective method for managing zoster-associated pain (ZAP), though the limited efficacy of and high recurrence rates associated with the procedure present concerns.
OBJECTIVES: This study aimed to investigate the safety and effectiveness of a higher-voltage HL-PRF treatment based on the original procedure for ZAP in the spinal area.
STUDY DESIGN: A prospective, randomized, controlled trial.
SETTING: Department of Pain Management, West China Hospital of Sichuan University.
METHODS: In this prospective trial, patients were randomly assigned to one of 2 groups. Group A received an initial voltage of 65 V, which was incrementally increased to the maximum tolerable level (<= 100 V). Group B maintained a steady voltage of 65 V throughout the treatment. The optimal puncture site was determined based on the distribution of rash and pain. With the use of a 16-slice spiral computed tomography (CT) scanner, the needle entry point, angle, and depth were calculated and marked. Under CT guidance, the needle was advanced to the upper edge of the intervertebral foramen, after which the PRF treatment instrument was connected. Accurate needle placement was confirmed through sensory and motor tests that induced a tingling sensation in the symptomatic nerve root area. Pain levels, negative emotional states, quality of life, and sleep quality were measured using the Visual Analog Scale (VAS), Brief Pain Inventory (BPI), Generalized Anxiety Disorder-7 (GAD-7), Patient Health Questionnaire-9 (PHQ-9), and Pittsburgh Sleep Quality Index (PSQI), respectively. The primary endpoint was the pain score at 12 weeks after treatment. Additional data collected included medication use, hospitalization costs and duration, and any adverse reactions.
RESULTS: Sixty patients were finally analyzed. The average voltage used in Group A was 85.79 ± 2.14V. As for the primary outcome, the 12-week VAS scores of Group A were significantly lower than those of Group B (P < 0.05), with scores on the BPI, GAD-7, PHQ-9, and PSQI having notable differences (P < 0.05). A significant difference in VAS score was also observed on the first day after the 2 treatments (P < 0.05). Pregabalin consumption was lower in Group A at 12 weeks (P < 0.05). No statistical differences in the areas of rescue analgesic use, adverse reaction incidence, or economic indicators were found between the groups.
LIMITATIONS: This study took place in a single-center setting and had a short follow-up period and a relatively small number of patients.
CONCLUSIONS: Using higher voltage in original HL-PRF treatments enhances pain relief, quality of life, and emotional well-being, in addition to reducing medication dependence. Multiple sessions might be preferable to a single treatment, with no additional cost or safety risks. Larger scale, long-term studies are needed to confirm these findings and guide clinical practice.
KEY WORDS: Zoster-associated pain, postherpetic neuralgia, pulsed radiofrequency, randomized controlled study
Read More
| |
|
ASIPP is now in collaboration with Curi Medical Liability Program
Since this malpractice insurance program officially launched in November 2018, ASIPP has signed up hundreds of providers with an average savings of 30%. This is professional liability insurance tailored to our specialty and will stand up for us and defend our practices.
Curi is a full-service advisory firm that serves physicians and their practices. Their valued advice is grounded in your priorities and elevated in your outcomes. They are driven by a deep understanding of your specific circumstances in medicine, business, and life. To read a few important points to keep in mind about the program, including discounts, administrative defense, cyber coverage, aggressive claims handling, and complimentary risk management CME activities, visit our website.
| | |
|
Group Purchasing Organization Offer Better Pricing and Creates Added Value
ASIPP has formed a partnership with Henry Schein and PedsPal, a national GPO that has a successful history of negotiating better prices on medical supplies and creating value-added services for independent physicians. Working with MedAssets, PedsPal provides excellent pricing on products like contrast media that alleviate some of the financial pressures you experience today.
Learn More
| | |
|
ASIPP, Fedora Healthcare Solutions Partnership
ASIPP offers our members the benefit of a unique revenue cycle management/ billing service.
We have received a tremendous amount of interest in the ASIPP billing and coding program.
Click here to learn more about the negotiated rate for practices and more!
| |
|
Like and follow ASIPP® on Facebook, X, and LinkedIn for the most
up-to-date news related to you, your practice, and your patients!
| | | | |